Adenocarcinoma of the fallopian tube: Report of a case with an unusual pattern of metastasis and response to combination chemotherapy

1984 ◽  
Vol 17 (2) ◽  
pp. 238-240 ◽  
Author(s):  
James A. Young ◽  
Charles R. Kossman ◽  
Mark R. Green
Keyword(s):  
Fallopian Tube ◽  
Combination Chemotherapy ◽  
Unusual Pattern

Combination chemotherapy in advanced adenocarcinoma of the fallopian tube

1992 ◽  
Vol 37 (4) ◽  
pp. 329-329
Author(s):  
Hg Muntz ◽  
Hm Tarraza ◽  
Ba Goff ◽  
Co Granai ◽  
Lw Rice ◽  
...  
Keyword(s):  
Fallopian Tube ◽  
Combination Chemotherapy

Cisplatin-based combination chemotherapy in carcinoma of the fallopian tube

1991 ◽  
Vol 42 (2) ◽  
pp. 156-160 ◽  
Author(s):  
Richard R. Barakat ◽  
Stephen C. Rubin ◽  
Patricia E. Saigo ◽  
Douglass Chapman ◽  
John L. Lewis ◽  
...  
Keyword(s):  
Fallopian Tube ◽  
Combination Chemotherapy

Phase I study of combination chemotherapy with irinotecan and gemcitabine for taxane/platinum resistant ovarian, fallopian tube, or primary peritoneal cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 5538-5538
Author(s):  
Kiyoshi Yoshino ◽  
Shoji Kamiura ◽  
Haruki Ogawa ◽  
Atsushi Tokuhira ◽  
Masahiko Takemura ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Fallopian Tube ◽  
Combination Chemotherapy ◽  
Ovarian Cancer Cell Line ◽  
Objective Response ◽  
Peritoneal Cancer ◽  
Platinum Resistant ◽  
Level 1 ◽  
Grade 3 ◽  
Level 2

5538 Background: Development of new regimen is required to overcome platinum resistant ovarian cancer. Irinotecan and gemcitabine have a synergistic effect to inhibit the growth of ovarian cancer cell line in vitro. The objective is to evaluate the feasibility of combination chemotherapy with irinotecan and gemcitabine for taxane/platinum resistant recurrent ovarian, fallopian tube or peritoneal cancer and to determine the recommended dose. Methods: Nine patients with measurable disease (age range 51-70 years) were enrolled. Patients were treated with irinotecan and gemcitabine on days 1 and 8 every 3 weeks with starting dose of level 1. Dose levels included irinotecan/gemcitabine: 65/650 (level 0), 80/800 (level 1), 100/1000 (level 2), mg/m2 respectively. Level 2 is defined as the maximum dose as used in other malignancies. Dose-limiting toxicity (DLT) was assessed during the first cycle; toxicities were monitored throughout the treatment according to the CTCAE v4.0. Treatment continued until disease progression or unacceptable toxicity. Results: In level 1 (n = 6), grade 3/4 neutropenia was observed in 5 patients. Grade 3 nausea and vomiting was observed in 1, grade 3 diarrhea in 1. One patient of level 1 experienced DLTs. In level 2 (n = 3), grade 3/4 neutropenia are observed in 3, anemia in 1, and thrombocytopenia in one patient. Other toxicities were mild. Three patients who received level 2 did not show DLT. The objective response was CR/PR/SD/PD, 0/2/5/2. Conclusions: The dose level of irinotecan 100 mg/m2 and gemcitabine 1000 mg/m2 on day 1 and 8 every 3 weeks is recommended for a phase II study. Clinical trial information: UMIN000005926.

Combination chemotherapy in advanced adenocarcinoma of the fallopian tube

1990 ◽  
Vol 40 (3) ◽  
pp. 268-273 ◽  
Author(s):  
Howard G. Muntz ◽  
Hector M. Tarraza ◽  
Barbara A. Goff ◽  
Cornelius O. Granai ◽  
Laurel W. Rice ◽  
...  
Keyword(s):  
Fallopian Tube ◽  
Combination Chemotherapy

Cisplatin-based combination chemotherapy in carcinoma of the fallopian tube

1991 ◽  
Vol 40 (2) ◽  
pp. 173
Author(s):  
R.R. Barakat ◽  
S.C. Rubin ◽  
W.J. Hoskins ◽  
W.B. Jones ◽  
T.B. Hakes ◽  
...  
Keyword(s):  
Fallopian Tube ◽  
Combination Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document